Evidence map›Paper›PMID 40537238›Full record

ArticleBMJ open2025

Promoting smoking cessation and preventing relapse to tobacco use following a smoke-free mental health inpatient stay (SCEPTRE feasibility study): a multicentre randomised controlled feasibility study protocol.

Petal Petersen Williams, Lisa Huddlestone, Emily Shoesmith, Samantha Brady, Alex Mitchell, Victoria Exley, Fraser Wiggins, Lesley Sinclair, Jodi Pervin, Michelle Horspool and 15 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Petal Petersen WilliamsMental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK petal.petersenwilliams@york.ac.uk.ORCID http://orcid.org/0000-0001-5535-2458
Lisa HuddlestoneMental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.
Emily ShoesmithMental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.
Samantha BradyYork Trials Unit, Department of Health Sciences, University of York, York, UK.ORCID http://orcid.org/0000-0001-7763-2776
Alex MitchellYork Trials Unit, Department of Health Sciences, University of York, York, UK.ORCID http://orcid.org/0000-0001-9311-2092
Victoria ExleyYork Trials Unit, Department of Health Sciences, University of York, York, UK.
Fraser WigginsYork Trials Unit, Department of Health Sciences, University of York, York, UK.
Lesley SinclairYork Trials Unit, Department of Health Sciences, University of York, York, UK.
Jodi PervinMental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.
Michelle HorspoolSheffield Health and Social Care NHS Foundation Trust, Sheffield, UK.
Moira LeahySheffield Health and Social Care NHS Foundation Trust, Sheffield, UK.
Claire PaulLeeds and York Partnership NHS Foundation Trust, Leeds, UK.
Lesley ColleyTees, Esk and Wear Valleys NHS Foundation Trust, Darlington, UK.
Lion ShahabDepartment of Behavioural Science and Health, University College London, London, UK.
Judith WatsonYork Trials Unit, Department of Health Sciences, University of York, York, UK.ORCID http://orcid.org/0000-0003-0694-3854
Catherine HewittYork Trials Unit, Department of Health Sciences, University of York, York, UK.
Simon HoughIndependent PPI Co-applicant, Cheshire, UK.
John BrittonDivision of Epidemiology, University of Nottingham, Nottingham, UK.
Tim ColemanCentre for Academic Primary Care, University of Nottingham, Nottingham, UK.
Simon GilbodyMental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.
Steve ParrottMental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.
Paul GaldasMental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.ORCID http://orcid.org/0000-0002-3185-205X
Gregor RussellResearch and Development, Bradford District Care NHS Foundation Trust, Bradford, UK.
Peter A CoventryMental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.
Elena RatschenMental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThousands of patients with mental illness are admitted to acute adult mental health wards every year in England, where local guidance recommends that all mental health settings be entirely smokefree. Mental health Trusts presently invest substantial effort and resources to implement smoke-free policies and to deliver tobacco dependence treatment to patients. Providing adequate support can help those who smoke remain abstinent or quit smoking during their smoke-free inpatient stay and beyond. At present, little is known about how best to support patients to prevent their return to pre-admission smoking behaviours after discharge from a smoke-free mental health inpatient stay. We have developed an intervention which includes targeted resources to support smoking-related behaviour change in patients following discharge from a smoke-free mental health setting. The aim of this trial is to determine the feasibility of a large-scale clinical trial to test the effectiveness and cost-effectiveness of the SCEPTRE intervention, compared with usual care. METHODS AND ANALYSIS: This feasibility study will be an individually randomised, controlled trial in eight National Health Service mental health Trusts recruiting adults (≥18 years) admitted to an acute adult mental health inpatient setting who smoke tobacco on admission, or at any point during their inpatient stay. Consenting participants will be randomised to receive a 12-week intervention consisting of components aimed at promoting or maintaining positive smoking-related behaviour change following discharge from a smoke-free mental health inpatient setting or usual care. Data will be collected at baseline, 3 months and a second timepoint between 4 and 6 months post-randomisation. With 64 participants (32 in each group), the trial will allow a participation rate of 15% and completion rate of 80% to be estimated within a 95% CI of ±3% and ±10%, respectively. The analysis will be descriptive and follow a prespecified plan. ETHICS AND DISSEMINATION: Ethics approval was obtained from the North West-Greater Manchester West Research Ethics Committee. We will share results widely through local, national and international academic, clinical and patient and public involvement networks. The results will be disseminated through conference presentations, peer-reviewed journals and will be published on the trial website: https://sceptreresearch.com/. TRIAL REGISTRATION NUMBER: ISRCTN77855199.

Indexed as

Mental DisordersSmoking CessationAdultCost-Benefit AnalysisEnglandFeasibility StudiesFemaleHumansInpatientsMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicSmoke-Free PolicyFeasibility StudiesMENTAL HEALTHPsychosocial InterventionSmoking ReductionTobacco Use

Identifiers

PMID40537238
PMCPMC12182159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.